Even though M&A will continue to loom large while the MedTech spectrum witnesses heavy consolidation in a teeming market, helping both survival and competitive edge, Nitin Potdar, M&A Partner, J. Sagar Associates, cautions that players cannot simply rely on the conducive pandemic environment to further their M&A/JV strategies. Patents, IPs, geographical reach, and quality of innovation will separate the leaders from the followers.
Please refer to the below document to read the full article by Nitin Potdar published in Express Healthcare Magazine – July edition.
Nitin specializes in Public and Private, Mergers & Acquisitions, Business Restructuring, Asset & Share Purchase, Transborder Alliances & Joint Ventures, Private Equity and general Corporate advisory.